BRAF and melanoma: Up to date, classical chemotherapy as well as discovered biomarkers have not been significant successful neither to diagnosis melanomas or to benefit patients, with rare exceptions, since only the gene CTLA4 and V600E mutational status of BRAF gene have been recognized as bona fide targets to treat metastatic disease [34], [35].